- Home
- FFIC vs CRVS Comparison
FFIC vs CRVS Comparison
Compare FFIC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFIC
- CRVS
- Stock Information
- Founded
- FFIC 1929
- CRVS 2014
- Country
- FFIC United States
- CRVS United States
- Employees
- FFIC N/A
- CRVS N/A
- Industry
- FFIC Major Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- FFIC Finance
- CRVS Health Care
- Exchange
- FFIC Nasdaq
- CRVS Nasdaq
- Market Cap
- FFIC 408.4M
- CRVS 459.0M
- IPO Year
- FFIC 1995
- CRVS 2016
- Fundamental
- Price
- FFIC $13.96
- CRVS $6.98
- Analyst Decision
- FFIC
- CRVS Strong Buy
- Analyst Count
- FFIC 0
- CRVS 3
- Target Price
- FFIC N/A
- CRVS $13.00
- AVG Volume (30 Days)
- FFIC 218.3K
- CRVS 744.5K
- Earning Date
- FFIC 10-29-2025
- CRVS 11-11-2025
- Dividend Yield
- FFIC 6.32%
- CRVS N/A
- EPS Growth
- FFIC N/A
- CRVS N/A
- EPS
- FFIC N/A
- CRVS N/A
- Revenue
- FFIC $137,137,000.00
- CRVS N/A
- Revenue This Year
- FFIC $113.87
- CRVS N/A
- Revenue Next Year
- FFIC $5.75
- CRVS N/A
- P/E Ratio
- FFIC N/A
- CRVS N/A
- Revenue Growth
- FFIC N/A
- CRVS N/A
- 52 Week Low
- FFIC $10.65
- CRVS $2.54
- 52 Week High
- FFIC $18.59
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- FFIC 56.75
- CRVS 62.35
- Support Level
- FFIC $13.55
- CRVS $6.76
- Resistance Level
- FFIC $14.12
- CRVS $7.39
- Average True Range (ATR)
- FFIC 0.32
- CRVS 0.42
- MACD
- FFIC -0.07
- CRVS 0.03
- Stochastic Oscillator
- FFIC 47.67
- CRVS 67.38
About FFIC Flushing Financial Corporation
Flushing Financial Corp operates as a bank holding company, which is engaged in the provision of banking and financial services. It provides Personal, Business, lending, Government banking, and Card services. Its principal business is attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, in originations and purchases of multi-family residential properties, commercial business loans, commercial real estate mortgage loans, construction loans, small business administration loans, and other small business loans.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).